Saw your post, and think it was/is an excellent po
Post# of 148166
(Total Views: 479)
Posted On: 08/17/2020 5:50:20 PM
Re: chuckles759 #50169
Saw your post, and think it was/is an excellent point. I noticed that NP repeated the statement that it is very hard to show mortality benefit.
The blog post/article you linked was from March 2020, and it didn't discuss any of the Covid trials (dexamethasone and itolizumab) out after that. I would guess that the dexamethasone study was solid (N=1500) but not the itolizumab one (N=30).
The blog author introduced an interesting concept (new to me) of the fragility index:
https://clincalc.com/Stats/FragilityIndex.aspx
I'm pretty sure the author would suggest that the itolizumab study was too small, and thus very "fragile" to a single subject or two dying or not.
I didn't calculate Fragility Index for itolizumab study but it could easily be done and compared if someone was bored enough to look.
The blog post/article you linked was from March 2020, and it didn't discuss any of the Covid trials (dexamethasone and itolizumab) out after that. I would guess that the dexamethasone study was solid (N=1500) but not the itolizumab one (N=30).
The blog author introduced an interesting concept (new to me) of the fragility index:
https://clincalc.com/Stats/FragilityIndex.aspx
I'm pretty sure the author would suggest that the itolizumab study was too small, and thus very "fragile" to a single subject or two dying or not.
I didn't calculate Fragility Index for itolizumab study but it could easily be done and compared if someone was bored enough to look.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼